Ipilimumab, a monoclonal antibody targeting CTLA-4, approved by the FDA in 2011 to treat melanoma patients, is also in phase III trials for NSCLC treatment [167,168,169,170]. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.